We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Throughout the year, you will have the opportunity to participate in campaigns that support endocrinology research, care, professionals, and patients. Contact us to get more involved: advocacy@endocrine.org.
Taking action by sending messages to your Congressional delegation makes a difference, and our online campaigns make it easy to do. Don't take it from us, hear from Rosa DeLauro, Ranking Member of the House Appropriations Committee, why your voice matters.
On June 26, the House Appropriations Subcommittee responsible for funding the NIH released their bill text for FY25 with a proposed budget of $48 billion. This is flat funding from FY24, which accounting for inflation, is a cut. The bill also includes a 7% cut for HHS, a 22% cut for CDC, harmful policy riders to eliminate Title X funding and restrict fetal tissue research, and assumes a restructuring of the NIH. This restructuring would see a number of institutes combined and some eliminated completely. It is imperative that your members of Congress hear from you about the harms of this bill and the importance of funding biomedical research.
Obesity has damaged our nation’s health, and its prevalence is increasing: over 42% of US adults and over 19% of children are estimated to have obesity. The Endocrine Society is urging the U.S. House of Representatives and Senate to pass the Treat and Reduce Obesity Act (TROA). This legislation would allow coverage of anti-obesity medications (AOMs) currently prohibited in the Medicare statute and expand access to intensive behavioral therapy (IBT) for obesity. It is critical that your Senators and Representatives hear from you on the importance of passing this legislation.
The Endocrine Society is urging the Senate to pass the bipartisan Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act. Last year, President Biden signed the Inflation Reduction Act into law, which capped insulin costs for Medicare beneficiaries. However, insulin remains unaffordable for people with private insurance. Join our campaign today to remind your Senators that addressing insulin affordability for people with private insurance is a top priority.
Read our newsletters covering the latest science-based information on endocrine-disrupting chemicals (EDCs) for policymakers in the European Union.
